NCT06768476View on ClinicalTrials.gov

CART123 + Ruxolitinib in Relapsed/Refractory AML

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

March 31, 2045

Study Completion Date

March 31, 2045

Conditions
Relapsed AMLRefractory AML
Interventions
BIOLOGICAL

CART123 Cells

1.3x10\^8 CART123 cells

DRUG

Ruxolitinib 10 MG

Twice Daily

DRUG

Ruxolitinib 5 MG

Twice Daily

Trial Locations (1)

19104

RECRUITING

University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of Pennsylvania

OTHER

NCT06768476 - CART123 + Ruxolitinib in Relapsed/Refractory AML | Biotech Hunter | Biotech Hunter